UNSPSC 51151902: Chlorzoxazone

This classification denotes a muscle relaxant with the molecular formula C7H4ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H0DE420U8G, chemically known as 2-benzoxazolinone, 5-chloro- but generally known as chlorzoxazone, which bears US NIH Compound Identifier 2733. European Medicines Agency schedules Chlorzoxazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06215MIG. The term CHLORZOXAZONE is an International Non-Proprietary Name.

UNSPSC 51151902 Chlorzoxazone, a Commodity code, shows a mismatch between its nominal scope and recent state and local procurement activity. The code name refers to a specific muscle relaxant pharmaceutical, but the posted opportunities under this code are procuring naloxone (an opioid antagonist), safe drug deactivation systems, and direct-to-manufacturer prescription programs — none of which align with chlorzoxazone's therapeutic classification or pharmaceutical product category. State and local issuing bodies tagged to this code include county health departments (Seminole County, Florida) and state health and human services commissions (Texas Health and Human Services Commission), but the actual goods and services being solicited fall outside the code's nominal definition.

Recent activity is sparse and geographically limited. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs for self-insured employee group health plans and state agencies, though this is an exploratory information-gathering vehicle rather than a formal competitive procurement with award timelines. The code shows little relevant recent activity aligned with its stated pharmaceutical definition, and the two opportunities posted under it address unrelated product categories and procurement mechanisms, suggesting either a data-entry error in code assignment or fundamental misalignment between the code's intended scope and current tagging practices in state and local procurement systems.